Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.
New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.
The Cancer Vaccine Institute’s 1st International Symposium on Immunotherapy will be held at The Royal Society in London on Friday 11 – Saturday 12 October 2013, with an ice-breaker drinks reception on the evening of Thursday 10th October 2013.
This important two day symposium will unite 300 clinicians and researchers to explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.
Key themes of the symposium:
- How chemotherapy alters the immunogenicity of tumour cells
- The effects of chemotherapy on immune regulation
- The effects of chemotherapy on effector cells of the immune system
- Clinical studies exploring the combinations of chemotherapy and immunotherapy
Senior Investigator, National Cancer Institute (NCI)
Director Translational Development, Immatics Biotechnologies GmbH, Tuebingen, Germany
Post Doctoral Research Assistant, St. George's University of London
Research Scientist, INSERM U848
Investigator, Head, Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, NCI
Research Assistant, St George's University of London
University of Adelaide
Hadassah-Hebrew University Medical Center
Associate Professor, VU University Medical Center
Assistant Professor, Division of Surgery Oncology, University of California, LA
Professor, Dept of Tumor Immunology, Radboud University Nijmegen
Program Leader, Translational Tumor Immunology, Wistar Institute, Philadelphia
Sienna University School of Medicine
Professor of Oncology, John Hopkins University, Baltimore, Maryland
Partner, Dermatologikum Berlin
Professor, Chair, Roswell Park Cancer Institute
Senior Research Fellow, St George's University of London
Anderson Cancer Centre
Principal, Cancer Vaccine Institute
Register now to take advantage of the early bird discount.
Register before 9th August 2013 to take advantage of the early bird discount and save over £40.
- Early Bird two day symposium pass 11 – 12 October: £351
- Early Bird two day symposium pass 11 – 12 October student rate £210
- Early Bird one day symposium pass £265, student rate £160
- Standard two day symposium pass, 11 – 12 October: £395
- Standard rate two day symposium pass, 11 – 12 October, student rate: £255
- Standard rate one day symposium pass, £300, student rate £195